Oliwia Zakerska-Banaszak
Overview
Explore the profile of Oliwia Zakerska-Banaszak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zakerska-Banaszak O, Zuraszek-Szymanska J, Eder P, Ladziak K, Slomski R, Skrzypczak-Zielinska M
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273536
Inflammatory bowel disease (IBD) is an incurable, chronic disorder of the gastrointestinal tract whose incidence increases every year. Scientific research constantly delivers new information about the disease and its multivariate,...
2.
Zakerska-Banaszak O, Gozdzik-Spychalska J, Gabryel M, Zuraszek J, Skrzypczak-Zielinska M, Slomski R, et al.
F1000Res
. 2024 Aug;
11:379.
PMID: 39185143
The main aim of this study was to evaluate whether selected polymorphic variants in genes from the inflammatory pathway can be predictors of pulmonary or digestive manifestation of cystic fibrosis,...
3.
Vestergaard M, Allin K, Eriksen C, Zakerska-Banaszak O, Arasaradnam R, Alam M, et al.
United European Gastroenterol J
. 2023 Dec;
12(1):22-33.
PMID: 38041519
Background: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affect millions of people worldwide with increasing incidence. Objectives: Several studies have shown a link between gut...
4.
Lykowska-Szuber L, Walczak M, Stawczyk-Eder K, Krela-Kazmierczak I, Eder P, Zakerska-Banaszak O, et al.
J Appl Genet
. 2023 Sep;
64(4):759-768.
PMID: 37658984
Anti-tumor necrosis factor (TNF) therapy is used to induce and maintain remission in Crohn's disease (CD) patients. However, primary non-responders to initial treatment constitute 20-40% of cases. The causes of...
5.
Mankowska-Wierzbicka D, Zuraszek J, Wierzbicka A, Gabryel M, Mahadea D, Baturo A, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830905
It is crucial to consider the importance of the microbiome and the gut-lung axis in the context of SARS-CoV-2 infection. This pilot study examined the fecal microbial composition of patients...
6.
Krela-Kazmierczak I, Zakerska-Banaszak O, Skrzypczak-Zielinska M, Lykowska-Szuber L, Szymczak-Tomczak A, Zawada A, et al.
Nutrients
. 2022 Jun;
14(12).
PMID: 35745251
Despite the increasing knowledge with regard to IBD (inflammatory bowel disease), including ulcerative colitis (UC) and Crohn's disease (CD), the etiology of these conditions is still not fully understood. Apart...
7.
Zakerska-Banaszak O, Lykowska-Szuber L, Walczak M, Zuraszek J, Zielinska A, Skrzypczak-Zielinska M
Toxics
. 2022 Apr;
10(4).
PMID: 35448412
The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications. Since then, they...
8.
Zakerska-Banaszak O, Tomczak H, Gabryel M, Baturo A, Wolko L, Michalak M, et al.
Sci Rep
. 2021 Jan;
11(1):2166.
PMID: 33495479
Ulcerative colitis (UC) is a chronic immune-mediated disorder, whose etiology is not fully understood and for which no effective treatment is available. Recently, research has focused on the dysbiosis of...
9.
Walczak M, Lykowska-Szuber L, Plucinska M, Stawczyk-Eder K, Zakerska-Banaszak O, Eder P, et al.
Front Pharmacol
. 2020 Sep;
11:1207.
PMID: 32922288
Anti-tumor necrosis factor (TNF) therapy is used for the induction and maintenance of remission in Crohn's disease (CD) patients. However, primary nonresponders to initial treatment constitute 20%-40% of cases. The...
10.
Mankowska-Wierzbicka D, Stelmach-Mardas M, Gabryel M, Tomczak H, Skrzypczak-Zielinska M, Zakerska-Banaszak O, et al.
Biomedicines
. 2020 Aug;
8(8).
PMID: 32756350
The modification of the microbiome through fecal microbiota transplantation (FMT) is becoming a very promising therapeutic option for inflammatory bowel disease (IBD) patients. Our pilot study aimed to assess the...